CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Inclusion Criteria: * Age ≥ 18 - \< 65 years. Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) based on WHO 2008 Lymphoma Classification * Follicular lymphomas (FLs) grade 3b is allowed Patients in at least stage II with age adjusted international prognostic score (IPI score) of 2 or 3: * Stage III /IV and elevated LDH * Stage III/IV and WHO performance status 2 - 3 * Stage II and elevated LDH and WHO performance status 2 - 3 And/or patients with * More than one extranodal site * Testicular lymphoma, stage IIE and higher * Paranasal sinus and orbital lymphoma with destruction of bone * Large cell infiltration of the bone marrow Exclusion Criteria: * Severe cardiac disease: cardiac function grade 3-4 * Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule * Pregnancy/lactation * Men and women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for six months after completion of treatment * Patients with other severe medical problems and with an expected short survival for non-lymphoma reasons * Known HIV positivity * Uncontrolled infectious disease, including meningeal infection * Active cancer except basal cell carcinoma and cervical carcinoma in situ during the last five years * Earlier treatment containing anthracyclins * Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol * CNS disease as diagnosed by MRI or cerebrospinal fluid (CSF) cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed * Pleural or peritoneal fluid that cannot be drained safely * Hypersensitivity to the active substance or any of the other ingredients * Patients participating in other clinical studies, unless followed for survival